One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Neuroendocrine Tumor Treatment Market

[ 英語タイトル ] Neuroendocrine Tumor Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0084111
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
- Amgen, Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb
- Eli Lilly & Company
- F. Hoffmann-La Roche Ltd.
- Ipsen
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceuticals, Ltd.

[Report Description]

Market Overview

The neuroendocrine tumor treatment market will show rapid growth due to the increasing prevalence of neuroendocrine carcinoma, technological advancements and rising number of government initiatives.

The prevalence of Neuroendocrine tumors is increasing across the globe, though being a rare disease as it is estimated that more than 12,000 people are found to be affected by neuroendocrine tumors every year in the United States. Therefore the increasing prevalence of neuroendocrine tumors helps in the adoption rate of the drugs for the treatment of this rare disease. The cost of development of these orphan drugs is significantly higher as compared with the other drugs which are expected to hamper the growth of the neuroendocrine tumors market during the forecast period.

There is also a significant increase in government initiatives and funding by various international organizations that is anticipated to boost the overall market in the near future.

Scope of the Report

As per the scope of the report, the neuroendocrine tumor is the rare tumor that arises from specialized body cells, called neuroendocrine cells, is known as neuroendocrine tumors. The neuroendocrine tumor arises from cells that produce hormones thus, it produces and releases hormones into the blood in response to signals received from the nervous system. It can occur anywhere in the body, but most commonly occurs in the pancreas, digestive tract, lungs, rectum, and appendix. The neuroendocrine tumor can be either benign (non-cancerous) or malignant (cancerous). The market is segmented by product, indication, end-user, and geography

Key Market Trends

Somatostatin Analogs is Expected to Dominate the Neuroendocrine Tumor Treatment Market During the Forecast Period

The Somatostatin Analogs (SSAs) are found to be the widely used drugs for the treatment of neuroendocrine carcinoma as they control cancer growth, symptoms, and target biomarkers. They are accounted for the largest revenue share owing to safe treatment procedure offered by SSAs. SSAs are found to be generally used to treat patients who are resistant to radiation therapy and surgery. Many SSAs are thus currently under clinical trial phase and waiting for approval, hence the market is expected to witness high growth over the forecast period.

North America is Anticipated to Dominate the Neuroendocrine Tumor Treatment Market

North America is found dominating the neuroendocrine tumors market, due to the rising incidence of neuroendocrine diseases, developed health care infrastructure, strong clinical pipeline, high level of awareness among people and the presence of key market players. There are also supportive insurance policies in this region facilitating neuroendocrine treatment, such as Medicare, Medicaid, and Tricare that helps in driving the overall growth of the market.

Competitive Landscape

The key players are found undertaking strategies such as product launches, regional expansion, partnership, and distribution agreements, to strengthen their market position. There are also various companies that are found focusing on organic growth strategies product approvals and others such as patents and events. The inorganic growth strategies activities witnessed in the market were acquisitions, and partnerships & collaborations.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Neuroendocrine Carcinoma
4.2.2 Technological Advancements
4.2.3 Rising Number of Government Initiatives
4.3 Market Restraints
4.3.1 High Cost of Development
4.3.2 Lack of Awareness Among People
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Products
5.1.1 Somatostatin Analogs (SSAs)
5.1.2 Targeted Therapy
5.1.3 Chemotherapy
5.1.4 Others
5.2 By Indication
5.2.1 Lungs
5.2.2 Pancreas
5.2.3 Gastrointestinal
5.2.4 Others
5.3 By End User
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Others
5.4 Geography
5.4.1 North America US Canada Mexico
5.4.2 Europe Germany UK France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Amgen, Inc
6.1.2 Boehringer Ingelheim International GmbH
6.1.3 Bristol-Myers Squibb
6.1.4 Eli Lilly & Company
6.1.5 F. Hoffmann-La Roche Ltd.
6.1.6 Ipsen
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Sanofi
6.1.10 Teva Pharmaceuticals, Ltd.




Recommended reports